Literature DB >> 22093028

Effect of prednisone administration on coagulation variables in healthy Beagle dogs.

Lara J Rose1, Marilyn E Dunn1, Virginie Allegret2, Christian Bédard3.   

Abstract

BACKGROUND: Long-term corticosteroid therapy has been associated with increased risk of thrombotic disease in dogs.
OBJECTIVE: The purpose of this prospective study was to use thrombelastography (TEG) and thrombin generation (TG) to detect development of a hypercoagulable state in healthy Beagle dogs receiving oral prednisone. We hypothesized that administration of corticosteroids would result in a hypercoagulable profile on TEG tracings and an increase in TG.
METHODS: Six healthy adult Beagles from the University of Montreal's research colony were used to conduct a prospective longitudinal study in which all dogs received 1 mg/kg of prednisone orally once daily for 2 weeks, followed by a 6-week washout period, and then 4 mg/kg of prednisone orally once daily for 2 weeks. TEG tracings on citrated whole blood and TG measurements on frozen-thawed platelet-poor plasma were obtained before prednisone administration (baseline), at the end of the washout period, and at the end of both corticosteroid trials.
RESULTS: Significant differences compared with baseline values were obtained for K, α, and MA, with tracings compatible with a hypercoagulable profile following both corticosteroid trials. There was a significant increase in endogenous thrombin potential only after low-dose (1 mg/kg) prednisone.
CONCLUSION: Administration of prednisone to healthy Beagles resulted in hypercoagulability as indicated by TEG tracings, whereas the effect on TG was more variable. Further studies are needed to determine the underlying mechanisms of hypercoagulability and its clinical impact.
© 2011 American Society for Veterinary Clinical Pathology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22093028     DOI: 10.1111/j.1939-165X.2011.00364.x

Source DB:  PubMed          Journal:  Vet Clin Pathol        ISSN: 0275-6382            Impact factor:   1.180


  9 in total

1.  Hemostatic profile and thromboembolic risk in healthy dogs treated with prednisone: a randomized controlled trial.

Authors:  Felipe Gazza Romão; Elza Fernanda Campos; Claudio Roberto Scabelo Mattoso; Regina Kiomi Takahira
Journal:  BMC Vet Res       Date:  2013-12-31       Impact factor: 2.741

2.  Bilateral Vertebral Venous Sinus Thrombosis Causing Cervical Spinal Cord Compression in a Dog.

Authors:  Kathryn E Rhue; Amanda R Taylor; Robert C Cole; Randolph L Winter
Journal:  Front Vet Sci       Date:  2017-02-08

Review 3.  Comparative pathophysiology and management of protein-losing enteropathy.

Authors:  Melanie D Craven; Robert J Washabau
Journal:  J Vet Intern Med       Date:  2019-02-14       Impact factor: 3.333

4.  Effects of Aspirin and Prednisone on Platelet Function and Thromboxane Synthesis in Healthy Dogs.

Authors:  John M Thomason; Allison P Mooney; Joshua M Price; Jacqueline C Whittemore
Journal:  Front Vet Sci       Date:  2019-11-15

5.  Hypercoagulability in dogs with chronic enteropathy and association with serum albumin concentration.

Authors:  Amy Dixon; Edward J Hall; Sophie Adamantos; Aarti Kathrani; Ciara McGrath; Vicki Black
Journal:  J Vet Intern Med       Date:  2021-02-01       Impact factor: 3.333

6.  Effects of clopidogrel and prednisone on platelet function in healthy dogs.

Authors:  John Thomason; Allison P Mooney; Joshua M Price; Jacqueline C Whittemore
Journal:  J Vet Intern Med       Date:  2020-04-04       Impact factor: 3.333

7.  Effects of immunosuppressive agents on the hemostatic system in normal dogs.

Authors:  John M Thomason; Todd M Archer; Robert W Wills; Andrew J Mackin
Journal:  J Vet Intern Med       Date:  2018-05-10       Impact factor: 3.333

8.  Pharmacokinetics of Oral Prednisone at Various Doses in Dogs: Preliminary Findings Using a Naïve Pooled-Data Approach.

Authors:  Lionel Sebbag; Jonathan P Mochel
Journal:  Front Vet Sci       Date:  2020-10-19

9.  Nephrotic syndrome-associated hypercoagulopathy is alleviated by both pioglitazone and glucocorticoid which target two different nuclear receptors.

Authors:  Amanda P Waller; Shipra Agrawal; Katelyn J Wolfgang; Jiro Kino; Melinda A Chanley; William E Smoyer; Bryce A Kerlin
Journal:  Physiol Rep       Date:  2020-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.